alphaveLINCOLN₹636.70

Lincoln Pharmaceuticals Limited

Annual Quarterly₹ CrorePeersSIGACHI THEMISMED BAJAJHCARE AMRUTANJANJAGSNPHARM WANBURY AHCLMcap ₹1,275 Cr

View

In ₹ Crore except Per Share 12 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	156.0	146.4	142.5	147.3	161.2	146.6	168.2	154.1	163.4	166.3	187.3	177.3
Other Income	8.7	11.0	7.0	10.4	10.0	9.0	-6.9	15.3	7.2	15.1	-4.2	24.3
Total Income	164.7	157.5	149.5	157.7	171.2	155.5	161.3	169.3	170.6	181.5	183.1	201.5
Expenses
+ Cost of Materials Consumed	49.7	56.9	51.9	52.7	57.1	50.2	53.9	61.0	57.2	47.7	73.7	58.6
+ Purchases of Stock-in-Trade	20.0	30.5	17.0	13.3	21.9	18.6	14.7	15.8	21.7	25.0	16.4	20.9
+ Changes in Inventories	4.2	-20.3	4.7	4.2	-6.7	-0.1	11.5	-7.4	-2.2	3.3	-1.1	5.6
+ Employee Benefit Expense	24.9	26.4	25.1	29.0	27.8	28.0	27.6	31.8	30.4	30.6	32.5	33.3
+ Finance Costs	0.4	0.2	0.5	0.4	0.3	0.7	0.4	0.2	0.2	0.3	0.3	0.3
+ Depreciation & Amortisation	2.6	2.8	2.7	3.2	3.2	3.2	3.2	3.5	3.6	3.7	3.7	3.9
+ Other Expenses	26.1	23.3	25.5	25.3	32.7	26.3	33.7	29.1	30.8	36.1	40.9	31.4
Total Expenses	127.8	119.8	127.3	128.2	136.4	126.8	145.1	133.9	141.8	146.7	166.4	154.0
EBITDA	31.1	29.7	18.4	22.7	28.4	23.7	26.7	23.8	25.4	23.6	24.9	27.4
EBIT	28.6	26.8	15.7	19.5	25.2	20.4	23.5	20.3	21.8	19.9	21.2	23.5
Profit
PBT before Exceptional Items	36.9	37.7	22.2	29.5	34.8	28.7	16.2	35.4	28.8	34.7	16.7	47.6
Pretax Income	36.9	37.7	22.2	29.5	34.8	28.7	16.2	35.4	28.8	34.7	16.7	47.6
+ Current Tax	8.6	7.2	4.1	5.5	5.1	8.0	6.7	4.1	8.5	6.0	8.7	5.4
+ Deferred Tax	0.6	2.5	-0.5	0.3	3.3	-0.1	-2.0	3.6	0.3	0.1	-3.6	6.0
Tax Expense	9.2	9.7	3.6	5.8	8.5	7.9	4.7	7.7	8.8	6.1	5.1	11.3
Net Income	27.7	28.0	18.6	23.7	26.3	20.8	11.6	27.7	20.0	28.6	11.6	36.2
+ Net Income — Continuing Ops	27.7	28.0	18.6	23.7	26.3	20.8	11.6	27.7	20.0	28.6	11.6	36.2
+ Other Comprehensive Income	-0.1	-0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.4
Total Comprehensive Income	27.6	28.0	18.9	23.7	26.3	20.8	11.6	27.7	20.0	28.6	13.2	36.7
Per Share
Basic EPS	13.81	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09
Diluted EPS	13.81	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.0	0.0	0.0	0.0	1.6	0.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.0	-0.0	-0.0	-0.0	-1.6	-0.4
+ Tax on Items NOT to be Reclassified — alt tag	—	—	—	-0.0	—	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	0.0	28.0	0.0	23.7	0.0	20.8	0.0	27.7	0.0	0.0	0.0	36.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	13.81	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09
Diluted EPS — Continuing Operations	13.81	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	82.2	79.4	68.9	77.0	88.9	77.9	88.0	84.7	86.6	90.4	98.2	92.1
Gross Margin %	52.67	54.19	48.36	52.31	55.16	53.17	52.34	54.96	53.02	54.33	52.44	51.97
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	36.9	37.7	22.2	29.5	34.8	28.7	16.2	35.4	28.8	34.7	16.7	47.6
Net Income Adj (tax-effected)	27.7	28.0	18.6	23.7	26.3	20.8	11.6	27.7	20.0	28.6	11.6	36.2
EPS Adj	13.81	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.